You are here: Home » News-ANI » Business
Business Standard

Aurobindo Pharma's $1 billion deal with Novartis unit Sandoz collapses

Health Medical Pharma


Aurobindo Pharma's planned acquisition of the US generic oral solids and dermatology businesses of Sandoz Inc has fallen apart.

Aurobindo said on Thursday it is calling off the proposed acquisition of US dermatology and three manufacturing units of Sandoz, a division of Swiss drugmaker Novartis.

"This decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines," it said in a statement.

In September 2018, Aurobindo had agreed to purchase Sandoz's US dermatology and generic pills for one billion dollars in the biggest overseas acquisition by an Indian drugmaker.

Of this, an upfront payment of 900 million dollars was offered and performance-based payouts of 100 million dollars.

Aurobindo had said the transaction would catapult it to the second position in dermatological drugs segment as well as the second largest generics company in the United States by prescriptions.

The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa and ANVISA Brazil.

The company's product portfolio is spread over seven major therapeutic and product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, anti-allergies and anti-diabetics supported by an outstanding R & D set-up.

It is marketing these products in more than 150 countries.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 02 2020. 10:54 IST